Combining two strategies to improve perfusion and drug delivery in solid tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 46, 2013, Pages 18632-18637

  Stylianopoulos, Triantafyllos ^a   Jain, Rakesh K ^b  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Mathematical modeling; Mechanical forces; Tumor microenvironment; Vessel decompression; Vessel permeability

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; BEVACIZUMAB; CEDIRANIB; DIPHTHERIA TOXIN; DOXORUBICIN; LOSARTAN; MONOCLONAL ANTIBODY DC101; NELFINAVIR; NEUTRALIZING ANTIBODY; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; SARIDEGIB; SEMAXANIB; SUNITINIB; TAXANE DERIVATIVE; VASCULOTROPIN ANTIBODY;

ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYDRAULIC CONDUCTIVITY; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SOLID TUMOR; SURGICAL TECHNIQUE; TISSUE PERFUSION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UPREGULATION; VASCULAR NORMALIZATION; VESSEL DECOMPRESSION;

MATHEMATICAL MODELING; MECHANICAL FORCES; TUMOR MICROENVIRONMENT; VESSEL DECOMPRESSION; VESSEL PERMEABILITY;

BIOMECHANICAL PHENOMENA; CAPILLARY PERMEABILITY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 84887478772     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1318415110     Document Type: Article

References (67)

1. Jain RK (1988) Determinants of tumor blood flow: A review. Cancer Res 48(10): 2641-2658.
2. Jain RK (2013) Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 31(17):2205-2218.
3. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7(9):987-989.
4. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
5. Goel S, et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121.
6. Goel S, Fukumura D, Jain RK (2012) Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proc Natl Acad Sci USA 109(20):E1214.
7. Dings RP, et al. (2007) Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13(11):3395-3402. (Pubitemid 46944928)
8. McGee MC, et al. (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76(5):1537-1545.
9. Winkler F, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553-563. (Pubitemid 40017699)
10. Huang Y, et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109(43):17561-17566.
11. Batchelor TT, et al. (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA, 10.1073/pnas.1318022110.
12. Sorensen AG, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402-407.
13. Emblem KE, et al. (2013) Vascular architecture imaging identifies patient responders to anti-angiogenic therapy. Nat Med 19(9):1178-1183.
14. Matsumoto S, et al. (2011) Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 71(20):6350-6359.
15. Eichhorn ME, et al. (2008) Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther 7(7):1006-1013.
16. Qayum N, et al. (2009) Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69(15):6347-6354.
17. Cohen-Jonathan E, et al. (2001) The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61(5):2289-2293. (Pubitemid 32692061)
18. Delmas C, et al. (2003) The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 9(16 Pt 1):6062-6068. (Pubitemid 38018094)
19. Leite de Oliveira R, et al. (2012) Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22(2):263-277.
20. Sawada J, et al. (2012) Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 22(2):235-249.
21. Kashiwagi S, et al. (2008) Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 14(3):255-257. (Pubitemid 351347918)
22. Goel S, et al. (2013) Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 105(16):1188-1201.
23. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59(15):3776-3782. (Pubitemid 29381886)
24. Padera TP, et al. (2004) Pathology: Cancer cells compress intratumour vessels. Nature 427(6976):695. (Pubitemid 38294577)
25. Stylianopoulos T, et al. (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109(38): 15101-15108.
26. Chauhan VP, et al. (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 4:2516, 10.1038/ncomms.3516.
27. Olive KP, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457-1461.
28. Jacobetz MA, et al. (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62(1):112-120.
29. Provenzano PP, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3): 418-429.
30. Liu J, et al. (2012) TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA 109(41):16618-16623.
31. Baish JW, et al. (1996) Role of tumor vascular architecture in nutrient and drug delivery: An invasion percolation-based network model. Microvasc Res 51(3):327-346. (Pubitemid 26162001)
32. Chauhan VP, et al. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7(6):383-388.
33. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95(8):4607-4612. (Pubitemid 28207960)
34. Kamoun WS, et al. (2010) Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods 7(8):655-660.
35. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK (1996) Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 52(1):27-46. (Pubitemid 26245691)
36. Yuan F, et al. (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93(25):14765-14770. (Pubitemid 26419043)
37. Mancuso MR, et al. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10):2610-2621. (Pubitemid 44511625)
38. Batchelor TT, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95. (Pubitemid 46075199)
39. Swabb EA, Wei J, Gullino PM (1974) Diffusion and convection in normal and neoplastic tissues. Cancer Res 34(10):2814-2822.
40. Jain RK (1987) Transport of molecules in the tumor interstitium: A review. Cancer Res 47(12):3039-3051.
41. Levick JR (1987) Flow through interstitium and other fibrous matrices. Q J Exp Physiol 72(4):409-437.
42. Baxter LT, Jain RK (1991) Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 41(1):5-23.
43. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12): 1421-1434.
44. Mok W, Stylianopoulos T, Boucher Y, Jain RK (2009) Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy. Clin Cancer Res 15(7):2352-2360.
45. O'Brien ME, et al.; CAELYX Breast Cancer Study Group (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440-449. (Pubitemid 38444547)
46. Gradishar WJ, et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794-7803. (Pubitemid 46657376)
47. Von Hoff DD, et al. (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol Suppl 31(abstr 4005).
48. Tong RT, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731-3736. (Pubitemid 38697278)
49. Kindler H, et al. (2007) A double-blind, placebocontrolled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of cancer and leukemia group B (CALGB). J Clin Oncol 25(18, Suppl):4508.
50. Philip PA (2008) Targeting angiogenesis in pancreatic cancer. Lancet 371(9630): 2062-2064.
51. Daldrup-Link HE, et al. (2004) Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Microcirculation 11(5):387-396. (Pubitemid 39618616)
52. Pastuskovas CV, et al. (2012) Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11(3):752-762.
53. Chen Y, Balthasar JP (2012) Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 14(4): 850-859.
54. Van der Veldt AA, et al. (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 21(1):82-91.
55. Arjaans M, et al. (2013) Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 73(11):3347-3355.
56. Fukumura D, Yuan F, Endo M, Jain RK (1997) Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150(2):713-725. (Pubitemid 27073798)
57. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 108(7):2909-2914.
58. Hidalgo M, Von Hoff DD (2012) Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 18(16):4249-4256.
59. Nakai Y, et al. (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103(11):1644-1648.
60. Wilop S, et al. (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135(10):1429-1435.
61. Keizman D, et al. (2011) Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer 47(13):1955-1961.
62. Conroy T, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825.
63. Stockmann C, et al. (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456(7223):814-818.
64. Rhim AD, et al. (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349-361.
65. Falanga A, Marchetti M, Vignoli A (2013) Coagulation and cancer: Biological and clinical aspects. J Thromb Haemost 11(2):223-233.
66. Pries AR, Höpfner M, le Noble F, Dewhirst MW, Secomb TW (2010) The shunt problem: Control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10(8):587-593.
67. Stylianopoulos T, Soteriou K, Fukumura D, Jain RK (2013) Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model. Ann Biomed Eng 41(1):68-77.